![Mark Litton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Litton
Directeur Général chez ATHIRA PHARMA, INC.
Fortune : 434 828 $ au 30/06/2024
Profil
Mark J.
Litton was the founder of Lundbeck Seattle BioPharmaceuticals, Inc. (founded in 2004) where he held the position of Secretary, Treasurer & Chief Business Officer from 2014 to 2018.
He is currently the President, Chief Executive Officer & Director at Athira Pharma, Inc. since 2019 and also serves as a Director at Lumen Bioscience, Inc. Dr. Litton previously worked as the Manager-Business Development at Sirna Therapeutics, Inc. from 1997 to 1999, Vice President-Business Development at Celltech Group Plc from 1999 to 2004, and Vice President-Business Development at Chiroscience Group Plc.
He also worked as a Research Associate at DNAX Research, Inc. from 1991 to 1994 and served as the President & Chief Operating Officer at Alpine Immune Sciences, Inc. from 2018 to 2019.
Dr. Litton holds an MBA degree from Santa Clara University (conferred in 1994), an undergraduate degree from the University of California, Santa Cruz (conferred in 1990), and a doctorate degree from the University of Stockholm (conferred in 1997).
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
ATHIRA PHARMA, INC.
0,43% | 26/03/2024 | 164 086 ( 0,43% ) | 434 828 $ | 30/06/2024 |
Postes actifs de Mark Litton
Sociétés | Poste | Début |
---|---|---|
ATHIRA PHARMA, INC. | Directeur Général | 16/06/2021 |
Lumen Bioscience, Inc.
![]() Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Mark Litton
Sociétés | Poste | Fin |
---|---|---|
ALPINE IMMUNE SCIENCES, INC. | President | 16/04/2019 |
ALDER BIOPHARMACEUTICALS, INC. | Fondateur | 01/08/2018 |
Celltech Group Plc
![]() Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Corporate Officer/Principal | 01/01/2004 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/01/1999 |
DNAX Research, Inc. | Corporate Officer/Principal | 01/01/1994 |
Formation de Mark Litton
University of Stockholm | Doctorate Degree |
Santa Clara University | Masters Business Admin |
University of California, Santa Cruz | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
ATHIRA PHARMA, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
![]() Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Celltech Group Plc
![]() Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
DNAX Research, Inc. | |
Chiroscience Group Plc | Commercial Services |
Lumen Bioscience, Inc.
![]() Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Health Technology |